메뉴 건너뛰기




Volumn 14, Issue 7, 2013, Pages 843-861

A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication)

Author keywords

Clarithromycin; Helicobacter pylori; Rescue; Salvage; Second line; Treatment

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; NITROIMIDAZOLE; RABEPRAZOLE; TETRACYCLINE; TINIDAZOLE;

EID: 84876062526     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.782286     Document Type: Review
Times cited : (70)

References (127)
  • 1
    • 60749112195 scopus 로고    scopus 로고
    • Pylori treatment: New wine in old bottles?
    • Vakil N. H. pylori treatment: new wine in old bottles? Am J Gastroenterol 2009;104(1):26-30
    • (2009) Am J Gastroenterol , vol.104 , Issue.1 , pp. 26-30
    • Vakil, N.H.1
  • 2
    • 77951229121 scopus 로고    scopus 로고
    • Sequential therapy for Helicobacter pylori eradication: A critical review
    • Gisbert JP, Calvet X, O'Connor A, et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44(5):313-25
    • (2010) J Clin Gastroenterol , vol.44 , Issue.5 , pp. 313-325
    • Gisbert, J.P.1    Calvet, X.2    O'Connor, A.3
  • 3
    • 80052022998 scopus 로고    scopus 로고
    • Review article: Non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori
    • Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011;34(6):604-17
    • (2011) Aliment Pharmacol Ther , vol.34 , Issue.6 , pp. 604-617
    • Gisbert, J.P.1    Calvet, X.2
  • 4
    • 0035999136 scopus 로고    scopus 로고
    • Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail
    • Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16(6):1047-57
    • (2002) Aliment Pharmacol Ther , vol.16 , Issue.6 , pp. 1047-1057
    • Gisbert, J.P.1    Pajares, J.M.2
  • 5
    • 25444490967 scopus 로고    scopus 로고
    • Helicobacter pylori "rescue" therapy after failure of two eradication treatments
    • Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 2005;10(5):363-72
    • (2005) Helicobacter , vol.10 , Issue.5 , pp. 363-372
    • Gisbert, J.P.1    Pajares, J.M.2
  • 6
    • 64849083887 scopus 로고    scopus 로고
    • "rescue" regimens after Helicobacter pylori treatment failure
    • Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008;14(35):5385-402
    • (2008) World J Gastroenterol , vol.14 , Issue.35 , pp. 5385-5402
    • Gisbert, J.P.1
  • 7
    • 79952054420 scopus 로고    scopus 로고
    • Rescue therapy after Helicobacter pylori eradication failure
    • Gisbert JP. Rescue therapy after Helicobacter pylori eradication failure. Gastroenterol Hepatol 2011;34(2):89-99
    • (2011) Gastroenterol Hepatol , vol.34 , Issue.2 , pp. 89-99
    • Gisbert, J.P.1
  • 8
    • 0033629462 scopus 로고    scopus 로고
    • Regular review: Treatment of Helicobacter pylori infection
    • de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. BMJ 2000;320(7226):31-4
    • (2000) BMJ , vol.320 , Issue.7226 , pp. 31-34
    • De Boer, W.A.1    Tytgat, G.N.2
  • 9
    • 0035901164 scopus 로고    scopus 로고
    • Estrategias terapeuticas para la infeccion por Helicobacter pylori
    • Calvet X, Gene E, Sanfeliu I. Estrategias terapeuticas para la infeccion por Helicobacter pylori. Med Clin (Barc) 2001;116(6):239
    • (2001) Med Clin (Barc) , vol.116 , Issue.6 , pp. 239
    • Calvet, X.1    Gene, E.2    Sanfeliu, I.3
  • 10
    • 0007429598 scopus 로고    scopus 로고
    • Guidelines for the management of Helicobacter pylori infection
    • Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology
    • Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93(12):2330-8
    • (1998) Am J Gastroenterol , vol.93 , Issue.12 , pp. 2330-2338
    • Howden, C.W.1    Hunt, R.H.2
  • 11
    • 0033788930 scopus 로고    scopus 로고
    • Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: A meta-analysis of eradication of Helicobacter pylori
    • Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14(10):1319-28
    • (2000) Aliment Pharmacol Ther , vol.14 , Issue.10 , pp. 1319-1328
    • Gisbert, J.P.1    Gonzalez, L.2    Calvet, X.3
  • 12
    • 35948981603 scopus 로고    scopus 로고
    • Evolution of Helicobacter pylori therapy from a meta-analytical perspective
    • Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 2007;12(Suppl 2):50-8
    • (2007) Helicobacter , vol.12 , Issue.SUPPL. 2 , pp. 50-58
    • Gisbert, J.P.1    Pajares, R.2    Pajares, J.M.3
  • 13
    • 84858243399 scopus 로고    scopus 로고
    • Maintenance of Helicobacter pylori eradication rates with triple therapy over 12 years in a Spanish hospital
    • Gisbert JP, McNicholl AG. Maintenance of Helicobacter pylori eradication rates with triple therapy over 12 years in a Spanish hospital. Helicobacter 2012;17(2):160-1
    • (2012) Helicobacter , vol.17 , Issue.2 , pp. 160-161
    • Gisbert, J.P.1    McNicholl, A.G.2
  • 14
    • 81355146380 scopus 로고    scopus 로고
    • Review article: The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough
    • Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011;34(11-12):1255-68
    • (2011) Aliment Pharmacol Ther , vol.34 , Issue.11-12 , pp. 1255-1268
    • Gisbert, J.P.1    Calvet, X.2
  • 15
    • 0032995208 scopus 로고    scopus 로고
    • Evaluation of treatment regimens to cure Helicobacter pylori infection - A meta-analysis
    • Laheij RJ, Rossum LG, Jansen JB, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta-analysis. Aliment Pharmacol Ther 1999;13(7):857-64
    • (1999) Aliment Pharmacol Ther , vol.13 , Issue.7 , pp. 857-864
    • Laheij, R.J.1    Rossum, L.G.2    Jansen, J.B.3
  • 16
    • 0032173042 scopus 로고    scopus 로고
    • Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States
    • Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998;93(9):1432-5
    • (1998) Am J Gastroenterol , vol.93 , Issue.9 , pp. 1432-1435
    • Vakil, N.1    Hahn, B.2    McSorley, D.3
  • 17
    • 4344592305 scopus 로고    scopus 로고
    • H pylori antibiotic resistance: Prevalence, importance, and advances in testing
    • Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53(9):1374-84
    • (2004) Gut , vol.53 , Issue.9 , pp. 1374-1384
    • Megraud, F.1
  • 18
    • 49249136450 scopus 로고    scopus 로고
    • Treatment of Helicobacter pylori infection
    • Egan BJ, Marzio L, O'Connor H, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2008;13(Suppl 1):35-40
    • (2008) Helicobacter , vol.13 , Issue.SUPPL. 1 , pp. 35-40
    • Egan, B.J.1    Marzio, L.2    O'Connor, H.3    O'Morain, C.4
  • 19
    • 79551539868 scopus 로고    scopus 로고
    • Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area
    • Yakoob J, Abid S, Abbas Z, Jafri SN. Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area. Br J Biomed Sci 2010;67(4):197-201
    • (2010) Br J Biomed Sci , vol.67 , Issue.4 , pp. 197-201
    • Yakoob, J.1    Abid, S.2    Abbas, Z.3    Jafri, S.N.4
  • 20
    • 84871139519 scopus 로고    scopus 로고
    • Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption
    • Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42
    • (2013) Gut , vol.62 , pp. 34-42
    • Megraud, F.1    Coenen, S.2    Versporten, A.3
  • 21
    • 35648937514 scopus 로고    scopus 로고
    • Helicobacter pylori and antibiotic resistance
    • Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007;56(11):1502
    • (2007) Gut , vol.56 , Issue.11 , pp. 1502
    • Megraud, F.1
  • 22
    • 84859589351 scopus 로고    scopus 로고
    • Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report
    • Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61(5):646-64
    • (2012) Gut , vol.61 , Issue.5 , pp. 646-664
    • Malfertheiner, P.1    Megraud, F.2    O'Morain, C.A.3
  • 23
    • 79952358825 scopus 로고    scopus 로고
    • Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection
    • Furuta T, Kato M, Sugimoto M, et al. Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection. Intern Med 2011;50(5):369-74
    • (2011) Intern Med , vol.50 , Issue.5 , pp. 369-374
    • Furuta, T.1    Kato, M.2    Sugimoto, M.3
  • 27
    • 0034847354 scopus 로고    scopus 로고
    • A randomized trial of lansoprazole, amoxicillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy
    • Magaret N, Burm M, Faigel D, et al. A randomized trial of lansoprazole, amoxicillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis 2001;19(2):174-8
    • (2001) Dig Dis , vol.19 , Issue.2 , pp. 174-178
    • Magaret, N.1    Burm, M.2    Faigel, D.3
  • 28
    • 84885480028 scopus 로고    scopus 로고
    • A 10-days PPI/AM regimen is significantly effective as second-line treatment in unsuccessfully treated patients by first-line PPI/AC regimens
    • Nagahara A, Miwa H, Ohkura R, et al. A 10-days PPI/AM regimen is significantly effective as second-line treatment in unsuccessfully treated patients by first-line PPI/AC regimens. Gastroenterology 2000;118(4 Suppl 2):A1281
    • (2000) Gastroenterology , vol.118 , Issue.4 SUPPL. 2
    • Nagahara, A.1    Miwa, H.2    Ohkura, R.3
  • 29
    • 0035722085 scopus 로고    scopus 로고
    • Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection
    • Nagahara A, Miwa H, Ohkura R, et al. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2001;16(6):613-18
    • (2001) J Gastroenterol Hepatol , vol.16 , Issue.6 , pp. 613-618
    • Nagahara, A.1    Miwa, H.2    Ohkura, R.3
  • 30
    • 4243737299 scopus 로고    scopus 로고
    • Randomised study on the impact of resistance on second-line treatment after failed metronidazole-clarithromycin containing triple therapy
    • Peitz U, Sulliga M, Nusch A, et al. Randomised study on the impact of resistance on second-line treatment after failed metronidazole-clarithromycin containing triple therapy. Gut 1998;43(Suppl 2):A82-3
    • (1998) Gut , vol.43 , Issue.SUPPL. 2
    • Peitz, U.1    Sulliga, M.2    Nusch, A.3
  • 31
    • 0345392623 scopus 로고    scopus 로고
    • High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin
    • Furuta T, Shirai N, Xiao F, et al. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003;50(54):2274-8
    • (2003) Hepatogastroenterology , vol.50 , Issue.54 , pp. 2274-2278
    • Furuta, T.1    Shirai, N.2    Xiao, F.3
  • 32
    • 33947375710 scopus 로고    scopus 로고
    • Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori
    • Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007;81(4):521-8
    • (2007) Clin Pharmacol Ther , vol.81 , Issue.4 , pp. 521-528
    • Furuta, T.1    Shirai, N.2    Kodaira, M.3
  • 33
    • 0042849164 scopus 로고    scopus 로고
    • High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin- metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection
    • Isomoto H, Inoue K, Furusu H, et al. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2003;18(1):101-7
    • (2003) Aliment Pharmacol Ther , vol.18 , Issue.1 , pp. 101-107
    • Isomoto, H.1    Inoue, K.2    Furusu, H.3
  • 34
    • 34447340220 scopus 로고    scopus 로고
    • Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy
    • Shirai N, Sugimoto M, Kodaira C, et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007;63(8):743-9
    • (2007) Eur J Clin Pharmacol , vol.63 , Issue.8 , pp. 743-749
    • Shirai, N.1    Sugimoto, M.2    Kodaira, C.3
  • 35
    • 33846017642 scopus 로고    scopus 로고
    • Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan
    • Fukuda S, Shimoyama T, Tanaka M, et al. Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan. Jpn J Infect Dis 2006;59(6):367-9
    • (2006) Jpn J Infect Dis , vol.59 , Issue.6 , pp. 367-369
    • Fukuda, S.1    Shimoyama, T.2    Tanaka, M.3
  • 36
    • 84885474779 scopus 로고    scopus 로고
    • Impact of efficacies of triple therapy using lafutidine plus amoxicillin-metronidazole for proton pump inhibitor-amoxicillin-clarithromycin treatment failures for Helicobacter pylori infection
    • Kudo T, Fujinami H, Hosokawa A, et al. Impact of efficacies of triple therapy using lafutidine plus amoxicillin-metronidazole for proton pump inhibitor-amoxicillin-clarithromycin treatment failures for Helicobacter pylori infection. Gastroenterology 2009;136(5):A-341
    • (2009) Gastroenterology , vol.136 , Issue.5
    • Kudo, T.1    Fujinami, H.2    Hosokawa, A.3
  • 37
    • 33644873329 scopus 로고    scopus 로고
    • Levofloxacin-versus metronidazole-based rescue therapy for H. pylori infection in Japan
    • Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin-versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005;37(11):821-5
    • (2005) Dig Liver Dis , vol.37 , Issue.11 , pp. 821-825
    • Matsumoto, Y.1    Miki, I.2    Aoyama, N.3
  • 38
    • 0037560114 scopus 로고    scopus 로고
    • Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?
    • Miwa H, Nagahara A, Kurosawa A, et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003;17(12):1545-51
    • (2003) Aliment Pharmacol Ther , vol.17 , Issue.12 , pp. 1545-1551
    • Miwa, H.1    Nagahara, A.2    Kurosawa, A.3
  • 39
    • 33748441770 scopus 로고    scopus 로고
    • Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection
    • Murakami K, Okimoto T, Kodama M, et al. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. Helicobacter 2006;11(5):436-40
    • (2006) Helicobacter , vol.11 , Issue.5 , pp. 436-440
    • Murakami, K.1    Okimoto, T.2    Kodama, M.3
  • 40
    • 38349125405 scopus 로고    scopus 로고
    • Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection
    • Murakami K, Okimoto T, Kodama M, et al. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J Clin Gastroenterol 2008;42(2):139-42
    • (2008) J Clin Gastroenterol , vol.42 , Issue.2 , pp. 139-142
    • Murakami, K.1    Okimoto, T.2    Kodama, M.3
  • 41
    • 40449141969 scopus 로고    scopus 로고
    • A new eradication resistance index as a predictor of metronidazole- containing second-line treatment of Helicobacter pylori
    • Nishizawa T, Suzuki H, Masaoka T, et al. A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori. Digestion 2007;76(3-4):215-20
    • (2007) Digestion , vol.76 , Issue.3-4 , pp. 215-220
    • Nishizawa, T.1    Suzuki, H.2    Masaoka, T.3
  • 42
    • 8544280733 scopus 로고    scopus 로고
    • Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population
    • Shimoyama T, Fukuda S, Mikami T, et al. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J Gastroenterol 2004;39(10):927-30
    • (2004) J Gastroenterol , vol.39 , Issue.10 , pp. 927-930
    • Shimoyama, T.1    Fukuda, S.2    Mikami, T.3
  • 43
    • 0032707837 scopus 로고    scopus 로고
    • Re-treatment after Helicobacter pylori eradication failure
    • Gisbert JP, Boixeda D, Bermejo F, et al. Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999;11(9):1049-54
    • (1999) Eur J Gastroenterol Hepatol , vol.11 , Issue.9 , pp. 1049-1054
    • Gisbert, J.P.1    Boixeda, D.2    Bermejo, F.3
  • 44
    • 79956120209 scopus 로고    scopus 로고
    • Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population
    • Hori K, Miwa H, Matsumoto T. Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter 2011;16(3):234-40
    • (2011) Helicobacter , vol.16 , Issue.3 , pp. 234-240
    • Hori, K.1    Miwa, H.2    Matsumoto, T.3
  • 45
    • 80052259224 scopus 로고    scopus 로고
    • Randomized comparison of two non-bismuth-containing rescue therapies for Helicobacter pylori
    • Hu TH, Chuah SK, Hsu PI, et al. Randomized comparison of two non-bismuth-containing rescue therapies for Helicobacter pylori. Am J Med Sci 2011;342(3):177-81
    • (2011) Am J Med Sci , vol.342 , Issue.3 , pp. 177-181
    • Hu, T.H.1    Chuah, S.K.2    Hsu, P.I.3
  • 46
    • 33646681664 scopus 로고    scopus 로고
    • Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: A multicenter study in the Tokyo Metropolitan Area
    • Matsuhisa T, Kawai T, Masaoka T, et al. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Helicobacter 2006;11(3):152-8
    • (2006) Helicobacter , vol.11 , Issue.3 , pp. 152-158
    • Matsuhisa, T.1    Kawai, T.2    Masaoka, T.3
  • 47
    • 0037245872 scopus 로고    scopus 로고
    • Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole-or rabeprazole-based triple therapy in Japan
    • Miki I, Aoyama N, Sakai T, et al. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole-or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 2003;15(1):27-33
    • (2003) Eur J Gastroenterol Hepatol , vol.15 , Issue.1 , pp. 27-33
    • Miki, I.1    Aoyama, N.2    Sakai, T.3
  • 48
    • 0037251258 scopus 로고    scopus 로고
    • Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance
    • Murakami K, Sato R, Okimoto T, et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003;17(1):119-23
    • (2003) Aliment Pharmacol Ther , vol.17 , Issue.1 , pp. 119-123
    • Murakami, K.1    Sato, R.2    Okimoto, T.3
  • 49
    • 10244249314 scopus 로고    scopus 로고
    • Second-line treatment for Helicobacter pylori infection in Japan: Proton pump inhibitor-based amoxicillin and metronidazole regimen
    • Nagahara A, Miwa H, Kawabe M, et al. Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen. J Gastroenterol 2004;39(11):1051-5
    • (2004) J Gastroenterol , vol.39 , Issue.11 , pp. 1051-1055
    • Nagahara, A.1    Miwa, H.2    Kawabe, M.3
  • 50
    • 62149140495 scopus 로고    scopus 로고
    • Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure
    • Ueki N, Miyake K, Kusunoki M, et al. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure. Helicobacter 2009;14(2):91-9
    • (2009) Helicobacter , vol.14 , Issue.2 , pp. 91-99
    • Ueki, N.1    Miyake, K.2    Kusunoki, M.3
  • 51
    • 0031932458 scopus 로고    scopus 로고
    • Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection
    • Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13(1):1-12
    • (1998) J Gastroenterol Hepatol , vol.13 , Issue.1 , pp. 1-12
    • Lam, S.K.1    Talley, N.J.2
  • 52
    • 0034639765 scopus 로고    scopus 로고
    • Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference
    • Gisbert JP, Calvet X, Gomollon F, Sainz R. Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference. Med Clin (Barc) 2000;114(5):185-95
    • (2000) Med Clin (Barc) , vol.114 , Issue.5 , pp. 185-195
    • Gisbert, J.P.1    Calvet, X.2    Gomollon, F.3    Sainz, R.4
  • 53
    • 79952487588 scopus 로고    scopus 로고
    • Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial
    • Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377(9769):905-13
    • (2011) Lancet , vol.377 , Issue.9769 , pp. 905-913
    • Malfertheiner, P.1    Bazzoli, F.2    Delchier, J.C.3
  • 54
    • 0141539362 scopus 로고    scopus 로고
    • Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: A randomized trial
    • Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18(6):627-33
    • (2003) Aliment Pharmacol Ther , vol.18 , Issue.6 , pp. 627-633
    • Nista, E.C.1    Candelli, M.2    Cremonini, F.3
  • 55
    • 0036668706 scopus 로고    scopus 로고
    • Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection
    • Boixeda D, Bermejo F, Martin-De-Argila C, et al. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16(8):1457-60
    • (2002) Aliment Pharmacol Ther , vol.16 , Issue.8 , pp. 1457-1460
    • Boixeda, D.1    Bermejo, F.2    Martin-De-Argila, C.3
  • 56
    • 33747623274 scopus 로고    scopus 로고
    • Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility
    • Cheon JH, Kim SG, Kim JM, et al. Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility. J Gastroenterol Hepatol 2006;21(10):1590-5
    • (2006) J Gastroenterol Hepatol , vol.21 , Issue.10 , pp. 1590-1595
    • Cheon, J.H.1    Kim, S.G.2    Kim, J.M.3
  • 57
    • 33645306299 scopus 로고    scopus 로고
    • Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection
    • Cheon JH, Kim N, Lee DH, et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006;11(1):46-51
    • (2006) Helicobacter , vol.11 , Issue.1 , pp. 46-51
    • Cheon, J.H.1    Kim, N.2    Lee, D.H.3
  • 58
    • 34347342910 scopus 로고    scopus 로고
    • Eradication rates of helicobacter pylori infection with second-line treatment: Non-ulcer dyspepsia compared to peptic ulcer disease
    • Chung SJ, Lee DH, Kim N, et al. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease. Hepatogastroenterology 2007;54(76):1293-6
    • (2007) Hepatogastroenterology , vol.54 , Issue.76 , pp. 1293-1296
    • Chung, S.J.1    Lee, D.H.2    Kim, N.3
  • 59
    • 84885482550 scopus 로고    scopus 로고
    • Trend of first-line and second-line eradication therapy for Helicobacter pylori infection in Korea
    • Chung JW, Jung HY, Choi KD, et al. Trend of first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Gastroenterology 2009;163(5):A-24
    • (2009) Gastroenterology , vol.163 , Issue.5
    • Chung, J.W.1    Jung, H.Y.2    Choi, K.D.3
  • 60
    • 79960438431 scopus 로고    scopus 로고
    • Second-line Helicobacter pylori eradication: A randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy
    • Chung JW, Lee JH, Jung HY, et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011;16(4):289-94
    • (2011) Helicobacter , vol.16 , Issue.4 , pp. 289-294
    • Chung, J.W.1    Lee, J.H.2    Jung, H.Y.3
  • 61
    • 84866764424 scopus 로고    scopus 로고
    • Efficacy of second-line treatment for Helicobacter pylori infection: Moxifloxacin-containing triple therapy vs. Bismuth-containing quadruple therapy
    • Chung KH, Lee DH, Kim N, et al. Efficacy of second-line treatment for Helicobacter pylori infection: moxifloxacin-containing triple therapy vs. Bismuth-containing quadruple therapy. Gastroenterology 2012;142(5):S-483-S-84
    • (2012) Gastroenterology , vol.142 , Issue.5
    • Chung, K.H.1    Lee, D.H.2    Kim, N.3
  • 62
    • 0002355995 scopus 로고    scopus 로고
    • Eficacia de dos tratamientos consecutivos en la erradicacion de Helicobacter pylori
    • Elizalde IR, Borda F, Jara C, et al. Eficacia de dos tratamientos consecutivos en la erradicacion de Helicobacter pylori. Anales Sis San Navarra 1998;21(Suppl 2):83-8
    • (1998) Anales Sis San Navarra , vol.21 , Issue.SUPPL. 2 , pp. 83-88
    • Elizalde, I.R.1    Borda, F.2    Jara, C.3
  • 63
    • 84973355533 scopus 로고    scopus 로고
    • Levofloxacin-based triple therapy in second-line treatment for Helicobacter pylori Eradication: Update
    • Finizio R, Nista EC, Candelli M, et al. Levofloxacin-based triple therapy in second-line treatment for Helicobacter pylori Eradication: update. Helicobacter 2005;10:528
    • (2005) Helicobacter , vol.10 , pp. 528
    • Finizio, R.1    Nista, E.C.2    Candelli, M.3
  • 64
    • 84885478822 scopus 로고    scopus 로고
    • Sequential and standard levofloxacin-based H. pylori eradicating regimens compared to quadruple therapy: Effect of levofloxacin dosage and way of administration
    • Franceschi F, Finizio R, Campanale M, et al. Sequential and standard levofloxacin-based H. pylori eradicating regimens compared to quadruple therapy: effect of levofloxacin dosage and way of administration. Gastroenterology 2011;140(5):S-58-9
    • (2011) Gastroenterology , vol.140 , Issue.5
    • Franceschi, F.1    Finizio, R.2    Campanale, M.3
  • 65
    • 0036192063 scopus 로고    scopus 로고
    • Effectiveness of two quadruple, tetracycline-or clarithromycin- containing, second-line, Helicobacter pylori eradication therapies
    • Georgopoulos SD, Ladas SD, Karatapanis S, et al. Effectiveness of two quadruple, tetracycline-or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002;16(3):569-75
    • (2002) Aliment Pharmacol Ther , vol.16 , Issue.3 , pp. 569-575
    • Georgopoulos, S.D.1    Ladas, S.D.2    Karatapanis, S.3
  • 66
    • 38149041576 scopus 로고    scopus 로고
    • Empirical rescue therapy after Helicobacter pylori treatment failure: A 10-year single-centre study of 500 patients
    • Gisbert JP, Gisbert JL, Marcos S, et al. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008;27(4):346-54
    • (2008) Aliment Pharmacol Ther , vol.27 , Issue.4 , pp. 346-354
    • Gisbert, J.P.1    Gisbert, J.L.2    Marcos, S.3
  • 67
    • 0033257421 scopus 로고    scopus 로고
    • Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitorbased therapy: A detailed, prospective analysis of 21 consecutive cases
    • Gomollon F, Ducons JA, Ferrero M, et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitorbased therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999;4(4):222-5
    • (1999) Helicobacter , vol.4 , Issue.4 , pp. 222-225
    • Gomollon, F.1    Ducons, J.A.2    Ferrero, M.3
  • 68
    • 33748448010 scopus 로고    scopus 로고
    • Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication
    • Kang MS, Park DI, Yun JW, et al. Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006;47(1):30-6
    • (2006) Korean J Gastroenterol , vol.47 , Issue.1 , pp. 30-36
    • Kang, M.S.1    Park, D.I.2    Yun, J.W.3
  • 69
    • 36248977613 scopus 로고    scopus 로고
    • Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacinbased triple therapy versus 2-week quadruple therapy
    • Kang JM, Kim N, Lee DH, et al. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacinbased triple therapy versus 2-week quadruple therapy. Helicobacter 2007;12(6):623-8
    • (2007) Helicobacter , vol.12 , Issue.6 , pp. 623-628
    • Kang, J.M.1    Kim, N.2    Lee, D.H.3
  • 70
    • 84885483491 scopus 로고    scopus 로고
    • Efficacy of 14 day quadruple therapy (OBMT) as 2nd line treatment for H. pylori in Korea: In the case of 1st line OAC treatment failure
    • Kim YS, Chun HJ, Kim KO, et al. Efficacy of 14 day quadruple therapy (OBMT) as 2nd line treatment for H. pylori in Korea: in the case of 1st line OAC treatment failure. Gastroenterology 2003;124 Suppl 1(4):M1825
    • (2003) Gastroenterology , vol.124 , Issue.4 SUPPL. 1
    • Kim, Y.S.1    Chun, H.J.2    Kim, K.O.3
  • 71
    • 64649086513 scopus 로고    scopus 로고
    • Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: A randomized controlled trial
    • Kuo CH, Hu HM, Kuo FC, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009;63(5):1017-24
    • (2009) J Antimicrob Chemother , vol.63 , Issue.5 , pp. 1017-1024
    • Kuo, C.H.1    Hu, H.M.2    Kuo, F.C.3
  • 72
    • 77954825680 scopus 로고    scopus 로고
    • Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy
    • Kuo CH, Wang SS, Hsu WH, et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter 2010;15(4):265-72
    • (2010) Helicobacter , vol.15 , Issue.4 , pp. 265-272
    • Kuo, C.H.1    Wang, S.S.2    Hsu, W.H.3
  • 73
    • 74349129496 scopus 로고    scopus 로고
    • Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: Effect of treatment duration and antibiotic resistance on the eradication rate in Korea
    • Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15(1):38-45
    • (2010) Helicobacter , vol.15 , Issue.1 , pp. 38-45
    • Lee, B.H.1    Kim, N.2    Hwang, T.J.3
  • 74
    • 34548528338 scopus 로고    scopus 로고
    • Prospective, randomized study of seven versus fourteen days omeprazole quadruple therapy for eradication of Helicobacter pylori infection in patients with duodenal ulcer after failure of omeprazole triple therapy
    • Mantzaris GJ, Petraki C, Petraki K, et al. Prospective, randomized study of seven versus fourteen days omeprazole quadruple therapy for eradication of Helicobacter pylori infection in patients with duodenal ulcer after failure of omeprazole triple therapy. Ann Gastroenterol 2005;18(3):330-5
    • (2005) Ann Gastroenterol , vol.18 , Issue.3 , pp. 330-335
    • Mantzaris, G.J.1    Petraki, C.2    Petraki, K.3
  • 75
    • 13944278454 scopus 로고    scopus 로고
    • Comparison of two management strategies for Helicobacter pylori treatment: Clinical study and cost-effectiveness analysis
    • Marko D, Calvet X, Ducons J, et al. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis. Helicobacter 2005;10(1):22-32
    • (2005) Helicobacter , vol.10 , Issue.1 , pp. 22-32
    • Marko, D.1    Calvet, X.2    Ducons, J.3
  • 76
    • 0034039422 scopus 로고    scopus 로고
    • Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens
    • Michopoulos S, Tsibouris P, Bouzakis H, et al. Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther 2000;14(6):737-44
    • (2000) Aliment Pharmacol Ther , vol.14 , Issue.6 , pp. 737-744
    • Michopoulos, S.1    Tsibouris, P.2    Bouzakis, H.3
  • 77
    • 84866758610 scopus 로고    scopus 로고
    • Substitution of tetracycline by amoxicillin in second-line Helicobacter pylori treatment conveys comparable success rates
    • Michopoulos S, Zampeli E, Anapliotis P, et al. Substitution of tetracycline by amoxicillin in second-line Helicobacter pylori treatment conveys comparable success rates. Gastroenterology 2012;142(5 Suppl 1):S-487-S-88
    • (2012) Gastroenterology , vol.142 , Issue.5 SUPPL. 1
    • Michopoulos, S.1    Zampeli, E.2    Anapliotis, P.3
  • 78
    • 84885469051 scopus 로고    scopus 로고
    • Levofloxacin, metronidazole and lansoprazole triple therapy compared to quadruple therapy as a second line treatment of Helicobacter pylori infection
    • Moon JY, Kim GH, Choi MK, et al. Levofloxacin, metronidazole and lansoprazole triple therapy compared to quadruple therapy as a second line treatment of Helicobacter pylori infection. Gastroenterology 2012;142(5 Suppl 1):S-483
    • (2012) Gastroenterology , vol.142 , Issue.5 SUPPL. 1
    • Moon, J.Y.1    Kim, G.H.2    Choi, M.K.3
  • 79
    • 27844560555 scopus 로고    scopus 로고
    • 10 days levofloxacin-based triple therapy in second-line treatment for Helicobacter pylori eradication
    • Nista EC, Candelli M, Fini L, et al. 10 days levofloxacin-based triple therapy in second-line treatment for Helicobacter pylori eradication. Gastroenterology 2004;126(2):576
    • (2004) Gastroenterology , vol.126 , Issue.2 , pp. 576
    • Nista, E.C.1    Candelli, M.2    Fini, L.3
  • 80
    • 2642514243 scopus 로고    scopus 로고
    • Helicobacter pylori infection in Turkish children: Comparison of diagnostic tests, evaluation of eradication rate, and changes in symptoms after eradication
    • Ozcay F, Kocak N, Temizel IN, et al. Helicobacter pylori infection in Turkish children: comparison of diagnostic tests, evaluation of eradication rate, and changes in symptoms after eradication. Helicobacter 2004;9(3):242-8
    • (2004) Helicobacter , vol.9 , Issue.3 , pp. 242-248
    • Ozcay, F.1    Kocak, N.2    Temizel, I.N.3
  • 81
    • 21644455056 scopus 로고    scopus 로고
    • Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection
    • Park SC, Chun HJ, Jung SW, et al. Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection. Korean J Gastroenterol 2004;44(3):136-41
    • (2004) Korean J Gastroenterol , vol.44 , Issue.3 , pp. 136-141
    • Park, S.C.1    Chun, H.J.2    Jung, S.W.3
  • 82
    • 0142187289 scopus 로고    scopus 로고
    • Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'
    • Perri F, Festa V, Merla A, et al. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2003;18(8):815-20
    • (2003) Aliment Pharmacol Ther , vol.18 , Issue.8 , pp. 815-820
    • Perri, F.1    Festa, V.2    Merla, A.3
  • 83
    • 60749100786 scopus 로고    scopus 로고
    • Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen
    • Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104(1):21-5
    • (2009) Am J Gastroenterol , vol.104 , Issue.1 , pp. 21-25
    • Rokkas, T.1    Sechopoulos, P.2    Robotis, I.3
  • 84
    • 0012033567 scopus 로고    scopus 로고
    • High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy
    • Sicilia B, Sierra E, Lago A, et al. High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy. Med Clin (Barc) 2000;115(17):641-3
    • (2000) Med Clin (Barc) , vol.115 , Issue.17 , pp. 641-643
    • Sicilia, B.1    Sierra, E.2    Lago, A.3
  • 85
    • 37249061706 scopus 로고    scopus 로고
    • Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy
    • Uygun A, Ozel AM, Yildiz O, et al. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. J Gastroenterol Hepatol 2008;23(1):42-5
    • (2008) J Gastroenterol Hepatol , vol.23 , Issue.1 , pp. 42-45
    • Uygun, A.1    Ozel, A.M.2    Yildiz, O.3
  • 86
    • 33750010851 scopus 로고    scopus 로고
    • Randomized comparison of two rescue therapies for Helicobacter pylori infection
    • Wu DC, Hsu PI, Chen A, et al. Randomized comparison of two rescue therapies for Helicobacter pylori infection. Eur J Clin Invest 2006;36(11):803-9
    • (2006) Eur J Clin Invest , vol.36 , Issue.11 , pp. 803-809
    • Wu, D.C.1    Hsu, P.I.2    Chen, A.3
  • 87
    • 79955601716 scopus 로고    scopus 로고
    • Helicobacter pylori infection: A randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies
    • Wu DC, Hsu PI, Tseng HH, et al. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore) 2011;90(3):180-5
    • (2011) Medicine (Baltimore) , vol.90 , Issue.3 , pp. 180-185
    • Wu, D.C.1    Hsu, P.I.2    Tseng, H.H.3
  • 88
    • 84885485314 scopus 로고    scopus 로고
    • Quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy -comparison of OBMT 7, 14 days regimen
    • Choung RS, Lee SW, Yim HJ, et al. Quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy -comparison of OBMT 7, 14 days regimen-. Gastrointestinal Endoscopy 2004;59(5): p. 152
    • (2004) Gastrointestinal Endoscopy , vol.59 , Issue.5 , pp. 152
    • Choung, R.S.1    Lee, S.W.2    Yim, H.J.3
  • 89
    • 84860154494 scopus 로고    scopus 로고
    • Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori
    • Chuah S. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter 2012;17(3):216-23
    • (2012) Helicobacter , vol.17 , Issue.3 , pp. 216-223
    • Chuah, S.1
  • 90
    • 80051508454 scopus 로고    scopus 로고
    • Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer
    • Ermis F, Akyuz F, Uyanikoglu A, et al. Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. South Med J 2011;104(8):579-83
    • (2011) South Med J , vol.104 , Issue.8 , pp. 579-583
    • Ermis, F.1    Akyuz, F.2    Uyanikoglu, A.3
  • 91
    • 34250201009 scopus 로고    scopus 로고
    • Levofloxacin based triple therapy as a second-line treatment for Helicobacter pylori infection after failure of standard triple therapy
    • Festa V, Perri F, Boschetto S, et al. Levofloxacin based triple therapy as a second-line treatment for Helicobacter pylori infection after failure of standard triple therapy. Gastroenterology 2002;122:W1200
    • (2002) Gastroenterology , vol.122
    • Festa, V.1    Perri, F.2    Boschetto, S.3
  • 92
    • 33846212615 scopus 로고    scopus 로고
    • Levofloxacin-vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure
    • Gisbert JP, Gisbert JL, Marcos S, et al. Levofloxacin-vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure. Helicobacter 2007;12(1):68-73
    • (2007) Helicobacter , vol.12 , Issue.1 , pp. 68-73
    • Gisbert, J.P.1    Gisbert, J.L.2    Marcos, S.3
  • 93
    • 37849047500 scopus 로고    scopus 로고
    • Second-line rescue therapy with levofloxacin after H. pylori treatment failure: A Spanish multicenter study of 300 patients
    • Gisbert JP, Bermejo F, Castro-Fernandez M, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008;103(1):71-6
    • (2008) Am J Gastroenterol , vol.103 , Issue.1 , pp. 71-76
    • Gisbert, J.P.1    Bermejo, F.2    Castro-Fernandez, M.3
  • 94
    • 84872915619 scopus 로고    scopus 로고
    • Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: Time trends in a Spanish Multicenter study of 1000 patients
    • [Epub ahead of print]
    • Gisbert J. Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish Multicenter study of 1000 patients. J Clin Gastroenterol 2012; [Epub ahead of print]
    • (2012) J Clin Gastroenterol
    • Gisbert, J.1
  • 95
    • 33748461592 scopus 로고    scopus 로고
    • A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures
    • Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter 2006;11(5):418-24
    • (2006) Helicobacter , vol.11 , Issue.5 , pp. 418-424
    • Lee, Y.C.1    Wu, H.M.2    Chen, T.H.3
  • 96
    • 77951743890 scopus 로고    scopus 로고
    • Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
    • Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010;59(5):572-8
    • (2010) Gut , vol.59 , Issue.5 , pp. 572-578
    • Liou, J.M.1    Lin, J.T.2    Chang, C.Y.3
  • 97
    • 84885484266 scopus 로고    scopus 로고
    • Second-line treatment for H. pylori eradication: A new levofloxacin based strategy
    • Nista EC, Candelli M, Di Caro S, et al. Second-line treatment for H. pylori eradication: a new levofloxacin based strategy. Gut 2002;51(Suppl 2):A100
    • (2002) Gut , vol.51 , Issue.SUPPL. 2
    • Nista, E.C.1    Candelli, M.2    Di Caro, S.3
  • 98
    • 1942459285 scopus 로고    scopus 로고
    • Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy
    • Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003;35(10):711-15
    • (2003) Dig Liver Dis , vol.35 , Issue.10 , pp. 711-715
    • Watanabe, Y.1    Aoyama, N.2    Shirasaka, D.3
  • 99
    • 77954671190 scopus 로고    scopus 로고
    • Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice
    • Zullo A, De Francesco V, Manes G, et al. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointestin Liver Dis 2010;19(2):131-4
    • (2010) J Gastrointestin Liver Dis , vol.19 , Issue.2 , pp. 131-134
    • Zullo, A.1    De Francesco, V.2    Manes, G.3
  • 100
    • 33644925601 scopus 로고    scopus 로고
    • Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure
    • Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23(1):35-44
    • (2006) Aliment Pharmacol Ther , vol.23 , Issue.1 , pp. 35-44
    • Gisbert, J.P.1    Morena, F.2
  • 101
    • 33645556634 scopus 로고    scopus 로고
    • Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: A meta-analysis
    • Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101(3):488-96
    • (2006) Am J Gastroenterol , vol.101 , Issue.3 , pp. 488-496
    • Saad, R.J.1    Schoenfeld, P.2    Kim, H.M.3    Chey, W.D.4
  • 102
    • 77957763723 scopus 로고    scopus 로고
    • Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent helicobacter pylori infection: A meta analysis
    • Li Y, Huang X, Yao L, et al. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010;122(13-14):413-22
    • (2010) Wien Klin Wochenschr , vol.122 , Issue.13-14 , pp. 413-422
    • Li, Y.1    Huang, X.2    Yao, L.3
  • 103
    • 0042825872 scopus 로고    scopus 로고
    • Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori
    • Chi CH, Lin CY, Sheu BS, et al. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther 2003;18(3):347-53
    • (2003) Aliment Pharmacol Ther , vol.18 , Issue.3 , pp. 347-353
    • Chi, C.H.1    Lin, C.Y.2    Sheu, B.S.3
  • 104
    • 18244409612 scopus 로고    scopus 로고
    • Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy
    • Kao AW, Cheng HC, Sheu BS, et al. Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy. J Gen Intern Med 2005;20(2):139-42
    • (2005) J Gen Intern Med , vol.20 , Issue.2 , pp. 139-142
    • Kao, A.W.1    Cheng, H.C.2    Sheu, B.S.3
  • 105
    • 19944384245 scopus 로고    scopus 로고
    • Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients
    • Koksal AS, Parlak E, Filik L, et al. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients. J Gastroenterol Hepatol 2005;20(4):637-42
    • (2005) J Gastroenterol Hepatol , vol.20 , Issue.4 , pp. 637-642
    • Koksal, A.S.1    Parlak, E.2    Filik, L.3
  • 106
    • 3943070468 scopus 로고    scopus 로고
    • Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy
    • Altintas E, Ulu O, Sezgin O, et al. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy. Turk J Gastroenterol 2004;15(2):90-3
    • (2004) Turk J Gastroenterol , vol.15 , Issue.2 , pp. 90-93
    • Altintas, E.1    Ulu, O.2    Sezgin, O.3
  • 107
    • 0034919018 scopus 로고    scopus 로고
    • A triple therapy regimen after failed Helicobacter pylori treatments
    • Zullo A, Hassan C, Campo SM, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001;15(8):1193-7
    • (2001) Aliment Pharmacol Ther , vol.15 , Issue.8 , pp. 1193-1197
    • Zullo, A.1    Hassan, C.2    Campo, S.M.3
  • 108
    • 0032990642 scopus 로고    scopus 로고
    • Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy
    • Rinaldi V, Zullo A, De Francesco V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999;13(2):163-8
    • (1999) Aliment Pharmacol Ther , vol.13 , Issue.2 , pp. 163-168
    • Rinaldi, V.1    Zullo, A.2    De Francesco, V.3
  • 109
    • 78650344748 scopus 로고    scopus 로고
    • Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection
    • Yoon H, Kim N, Kim JY, et al. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. J Gastroenterol Hepatol 2011;26(1):44-8
    • (2011) J Gastroenterol Hepatol , vol.26 , Issue.1 , pp. 44-48
    • Yoon, H.1    Kim, N.2    Kim, J.Y.3
  • 110
    • 80052355937 scopus 로고    scopus 로고
    • Helicobacter pylori infection: Is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients
    • Urgesi R, Pelecca G, Cianci R, et al. Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients. Can J Gastroenterol 2011;25(6):315-18
    • (2011) Can J Gastroenterol , vol.25 , Issue.6 , pp. 315-318
    • Urgesi, R.1    Pelecca, G.2    Cianci, R.3
  • 111
    • 79960458098 scopus 로고    scopus 로고
    • Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multicentre clinical trial
    • Liou JM, Chen CC, Chen MJ, et al. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2011;66(8):1847-52
    • (2011) J Antimicrob Chemother , vol.66 , Issue.8 , pp. 1847-1852
    • Liou, J.M.1    Chen, C.C.2    Chen, M.J.3
  • 112
    • 0036841850 scopus 로고    scopus 로고
    • The effect of Helicobacter pylori retreatment with ranitidine bismuth citrate, clarithromycin, and metronidazole depends on the first-line therapy
    • Farup PG, Lange OJ, Tholfsen J, et al. The effect of Helicobacter pylori retreatment with ranitidine bismuth citrate, clarithromycin, and metronidazole depends on the first-line therapy. J Clin Gastroenterol 2002;35(5):379-82
    • (2002) J Clin Gastroenterol , vol.35 , Issue.5 , pp. 379-382
    • Farup, P.G.1    Lange, O.J.2    Tholfsen, J.3
  • 113
    • 0033978868 scopus 로고    scopus 로고
    • Efficacy of a multistep strategy for Helicobacter pylori eradication
    • Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14(1):79-83
    • (2000) Aliment Pharmacol Ther , vol.14 , Issue.1 , pp. 79-83
    • Gasbarrini, A.1    Ojetti, V.2    Armuzzi, A.3
  • 114
    • 77649186287 scopus 로고    scopus 로고
    • Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin
    • Gisbert JP, Perez-Aisa A, Castro-Fernandez M, et al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis 2010;42(4):287-90
    • (2010) Dig Liver Dis , vol.42 , Issue.4 , pp. 287-290
    • Gisbert, J.P.1    Perez-Aisa, A.2    Castro-Fernandez, M.3
  • 115
    • 4243746067 scopus 로고    scopus 로고
    • "Rescue" therapy including ranitidine bismuth citrate + minocycline + amoxicillin for eradication of Helicobacter pylori in previous H.P. treatment failure
    • Cudia B, Romano M, Gioe FP, et al. "Rescue" therapy including ranitidine bismuth citrate + minocycline + amoxicillin for eradication of Helicobacter pylori in previous H.P. treatment failure. Gut 1997;41(Suppl 1):A103
    • (1997) Gut , vol.41 , Issue.SUPPL. 1
    • Cudia, B.1    Romano, M.2    Gioe, F.P.3
  • 116
    • 79960438847 scopus 로고    scopus 로고
    • Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: A randomized pilot study
    • Gu LY, Lin WW, Lu H, et al. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study. Helicobacter 2011;16(4):284-8
    • (2011) Helicobacter , vol.16 , Issue.4 , pp. 284-288
    • Gu, L.Y.1    Lin, W.W.2    Lu, H.3
  • 117
    • 58149299670 scopus 로고    scopus 로고
    • Sequential therapy vs standard triple therapies for Helicobacter pylori infection: A meta-analysis
    • Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009;34(1):41-53
    • (2009) J Clin Pharm Ther , vol.34 , Issue.1 , pp. 41-53
    • Tong, J.L.1    Ran, Z.H.2    Shen, J.3    Xiao, S.D.4
  • 118
    • 34948911342 scopus 로고    scopus 로고
    • The sequential therapy regimen for Helicobacter pylori eradication: A pooled-data analysis
    • Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56(10):1353-7
    • (2007) Gut , vol.56 , Issue.10 , pp. 1353-1357
    • Zullo, A.1    De Francesco, V.2    Hassan, C.3
  • 119
    • 45549100532 scopus 로고    scopus 로고
    • Meta-analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment
    • Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148(12):923-31
    • (2008) Ann Intern Med , vol.148 , Issue.12 , pp. 923-931
    • Jafri, N.S.1    Hornung, C.A.2    Howden, C.W.3
  • 120
    • 72949096113 scopus 로고    scopus 로고
    • Sequential therapy or triple therapy for Helicobacter pylori infection: Systematic review and meta-analysis of randomized controlled trials in adults and children
    • quiz 1080
    • Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104(12):3069-79; quiz 1080
    • (2009) Am J Gastroenterol , vol.104 , Issue.12 , pp. 3069-3079
    • Gatta, L.1    Vakil, N.2    Leandro, G.3
  • 121
    • 84859549239 scopus 로고    scopus 로고
    • Meta-analysis of sequential vs standard triple therapy for Helicobacter pylori eradication
    • Gisbert JP, Nyssen OP, McNicholl AG, et al. Meta-analysis of sequential vs standard triple therapy for Helicobacter pylori eradication. Helicobacter 2011;16(Suppl 1):131
    • (2011) Helicobacter , vol.16 , Issue.SUPPL. 1 , pp. 131
    • Gisbert, J.P.1    Nyssen, O.P.2    McNicholl, A.G.3
  • 122
    • 84859554392 scopus 로고    scopus 로고
    • Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
    • Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012;5:23-34
    • (2012) Clin Exp Gastroenterol , vol.5 , pp. 23-34
    • Gisbert, J.P.1    Calvet, X.2
  • 123
    • 35548969772 scopus 로고    scopus 로고
    • Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: Role of bacterial resistance
    • Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007;39(11):1001-5
    • (2007) Dig Liver Dis , vol.39 , Issue.11 , pp. 1001-1005
    • Perna, F.1    Zullo, A.2    Ricci, C.3
  • 124
    • 33646185810 scopus 로고    scopus 로고
    • Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: A pilot study
    • Zullo A, De Francesco V, Hassan C. Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study. Therapy 2006;3:251-4
    • (2006) Therapy , vol.3 , pp. 251-254
    • Zullo, A.1    De Francesco, V.2    Hassan, C.3
  • 125
    • 77954386659 scopus 로고    scopus 로고
    • Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice
    • Pontone S, Standoli M, Angelini R, Pontone P. Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice. Dig Liver Dis 2010;42(8):541-3
    • (2010) Dig Liver Dis , vol.42 , Issue.8 , pp. 541-543
    • Pontone, S.1    Standoli, M.2    Angelini, R.3    Pontone, P.4
  • 126
    • 84863578116 scopus 로고    scopus 로고
    • Helicobacter pylori infection: Sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate
    • Manfredi M, Bizzarri B, De'angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter 2012;17(4):246-53
    • (2012) Helicobacter , vol.17 , Issue.4 , pp. 246-253
    • Manfredi, M.1    Bizzarri, B.2    De'Angelis, G.L.3
  • 127
    • 84866774549 scopus 로고    scopus 로고
    • Second-line rescue triple therapy with levofloxacin after failure of quadruple non-bismuth "sequential" or "concomitant" treatment
    • Gisbert JP, Marin AC, Molina-Infante J. Second-line rescue triple therapy with levofloxacin after failure of quadruple non-bismuth "Sequential" or "Concomitant" treatment. Gastroenterology 2012;142(5 Suppl 1):S-482
    • (2012) Gastroenterology , vol.142 , Issue.5 SUPPL. 1
    • Gisbert, J.P.1    Marin, A.C.2    Molina-Infante, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.